Jul 10, 2025, 10:15 AM by

ClearNote Health, a company focused on improving early detection for some of the deadliest cancers, today announced that it has received UK Conformity Assessed marking for its Avantect® Pancreatic Cancer Test. The UKCA mark, established as part of the United Kingdom’s independent product safety regulatory framework following its departure from the European Union, signifies compliance with UK medical device regulations and paves the way for commercial availability in the UK market.

Jul 10, 2025, 01:00 AM by User Not Found

Bio-IT World | David Hewlett, renowned for portraying Dr. Rodney McKay in the Stargate franchise, recently joined Trends from the Trenches podcast to discuss the fascinating intersection of Hollywood, science communication, and lifelong learning. Hewlett and host Ari Berman explore how entertainment can serve as a powerful gateway to scientific curiosity and innovation.

Jul 9, 2025, 09:14 AM by

Bio-Rad Laboratories today announced the launch of four new Droplet Digital™ PCR (ddPCR™) platforms. The newly introduced instruments include Bio-Rad’s QX Continuum™ ddPCR system along with the QX700™ series of ddPCR platforms acquired as part of the company’s recently completed acquisition of digital PCR developer Stilla Technologies.

Jul 9, 2025, 09:14 AM by

July 8 2025 – Cambridge UK – Cresset, a leading provider of innovative solutions for the digitization of drug discovery, announces the acquisition of Molab.ai, a pioneer in artificial intelligence technologies tailored for molecular research. This strategic acquisition will combine Cresset’s powerful computational chemistry platform with Molab.ai’s proven capability to build highly predictive ADME models. It marks a significant step in Cresset’s mission to empower scientists with cutting-edge tools to accelerate drug discovery.

Jul 9, 2025, 09:14 AM by

Proceeds will accelerate Optibrium’s product development and expand the global reach of its computational chemistry and AI-driven discovery technology

Jul 9, 2025, 09:14 AM by

SPT Labtech today announced a strategic collaboration with Semarion. The partnership will integrate SPT Labtech’s firefly® liquid handling platform with Semarion’s SemaCyte® microcarrier technology to develop a flexible, scalable, and automated workflow that simplifies and accelerates key stages of adherent cell assay development.

Jul 9, 2025, 01:00 AM by User Not Found

Bio-IT World | Consumer genomics pioneer 23andMe will be returning to its co-founder and former CEO as Anne Wojcicki’s TTAM Research Institute outbids Regeneron to buy 23andMe out of bankruptcy—as long as no more state attorneys general object. The current iteration of the sale is expected to close on July 8.

Jul 8, 2025, 01:00 AM by User Not Found

Bio-IT World | Pangaea Data has entered into a collaboration agreement with Alexion to develop an Artificial Intelligence Clinical Decision Support System; Dell Technologies will develop NERSC-10, the next flagship supercomputer at the National Energy Research Scientific Computing Center; and more.

Jul 7, 2025, 08:29 AM by

Jul 7, 2025, 08:29 AM by

CD Bioparticles announces quality Purified Exosomes to support research in drug delivery.

Jul 7, 2025, 08:29 AM by

Jul 3, 2025, 08:19 AM by

PHARMASEAL, provider of the Engility® Trial Management Platform consisting of a Clinical Trial Management System (CTMS) CTMS and Electronic Trial Master File (eTMF), has announced a Technology Integration Partnership with Viedoc, a global leader in Electronic Data Capture (EDC) and eClinical technologies. This collaboration integrates PHARMASEAL’s advanced CTMS platform with Viedoc’s cutting-edge EDC capabilities, including its flagship product Viedoc Clinic, to deliver a more integrated solution for life science companies managing clinical trials worldwide.

Jul 3, 2025, 08:19 AM by

The research will focus on developing faster and more accurate methods for predicting drug metabolism

Jul 3, 2025, 01:00 AM by User Not Found

Bio-IT World | In a commentary published last week in Cell, researchers from the Arc Institute introduced the “Virtual Cell Challenge,” a public competition with a grand prize worth $100,000 for the machine learning model that best predicts how cells will respond to genetic perturbations.

Jul 2, 2025, 08:36 AM by

Femasys has received regulatory approvals in Australia and New Zealand for its innovative infertility solutions—FemaSeed®, a first-line, intratubal insemination treatment, and FemVue®, a diagnostic tool for assessing fallopian tube patency. These approvals mark a strategic expansion of the company’s global footprint and further validate its mission to offer more accessible, less invasive, and cost-effective fertility care. With FemaSeed shown to more than double pregnancy rates over traditional IUI in clinical trials, and FemVue enabling real-time fertility diagnostics in-office, this milestone offers new hope to patients facing infertility and strengthens Femasys’ commercial potential in international markets.

Jul 2, 2025, 08:36 AM by

Jul 2, 2025, 08:36 AM by

Jul 2, 2025, 08:35 AM by

Gene by Gene Supports Landmark Pharmacogenomics Trial to Personalize Prescribing in NHS Scotland

Jul 2, 2025, 01:00 AM by User Not Found

Bio-IT World | Consumer genomics pioneer 23andMe will be returning to its co-founder and former CEO as Anne Wojcicki’s TTAM Research Institute outbids Regeneron to buy 23andMe out of bankruptcy—as long as no more state attorneys general object. The current iteration of the sale is expected to close on July 8.

Jul 1, 2025, 08:19 AM by